Bristol Myers Squibb (BMY): Pulmonary fibrosis drug admilparant hits Phase 3 goal at 60 mg

Bristol Myers said admilparant met the primary goal in its Phase 3 ALOFT-IPF trial at 60 mg, but the 120 mg dose slowed lung decline without a statistically significant gain. Shares fell about 3% Monday. Size of the benefit was not disclosed.

Sources

• Bristol Myers Squibb, Phase 3 ALOFT-IPF trial met primary endpoint
• Investing.com, Bristol Myers Squibb's admilparant meets phase 3 IPF trial goal